Direct oral anticoagulant and AKI: Apixaban-induced acute interstitial nephritis

Abstract

Direct oral anticoagulants (DOACs) - dabigatran, rivaroxaban, apixaban and edoxaban - are changing the landscape of clinical practice for patients requiring short and long-term anticoagulation. We report a patient with no history of kidney disease developing acute interstitial nephritis (AIN) after starting a DOAC, apixaban. To date, this is the first biopsy proven case of apixaban-induced AIN.